[ET Net News Agency, 11 December 2017] Jefferies Research lifted its target price for
Sino Biopharmaceutical (SBP)(01177) to HK$13 from HK$12.5, and maintained its "buy"
rating.
The research house hosted a tour to SBP's 7 sites in Nanjing, Beijing, Lianyungang and
Qingdao last week, and met executive director Stephen Tse and key management: (1)
Management guided mid-teens sales growth in 2018, with RZ/Ganmei to recover, Esomeprazole
to continue strong, and new drugs to contribute; (2) Management also guided
better-than-sales profit growth in 2018 based on improving GM and stable SG&A. (3) Tide's
pipeline is well fledged in 2018-22, beyond expectation. (KL)
WoW WoW星期三:健康網購產品低至$99 (只限今天)► 立即行動